A recent study reveals that weight regain can happen quickly after discontinuing GLP-1 obesity drugs, reigniting concerns about long-term sustainability
GLP-1 RAs are currently being explored for use in various new areas, such as cardiovascular disease, non-alcoholic steatohepatitis (NASH), Alzheimer's disease, and chronic kidney disease
75% comes from the diet, particularly in red meat and dairy products
Before escalating to address a stall, audit protein intake, training volume, and overall caloric intake first
Do not discontinue or skip Mounjaro doses without medical advice, as this may affect glycaemic control in patients with diabetes